UTHRNasdaqPharmaceutical PreparationsFiscal year ends December 31
UNITED THERAPEUTICS Corp
Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Aug 5, 2026
$543.15+10.03 (+1.88%)
Close on Oct 19, 2026
- Market cap
- $24.88B
- P/E (TTM)
- 19.4
- Dividend yield
- –
UNITED THERAPEUTICS Corp revenue by segment
By business segment
By product or service
| Revenue | Q2 26 | Q1 26 | Q4 25 | Q3 25 | Q2 25 | Q1 25 | Q4 24 | Q3 24 | Q2 24 | Q1 24 | Q4 23 | Q3 23 | % of revenue | YoY |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Total Tyvaso | $452.60M | $457.50M | $464.30M | $478.00M | $469.60M | $466.30M | $415.90M | $433.80M | $398.20M | $372.50M | $350.60M | $325.80M | 57.8% | -3.6% |
| Tyvaso DPI | $326.60M | $330.30M | $338.60M | $336.20M | $315.20M | $302.50M | $273.20M | $274.60M | $258.30M | $227.50M | $213.70M | $205.10M | 41.7% | +3.6% |
| Remodulin | $126.30M | $126.60M | $128.00M | $125.90M | $134.70M | $138.20M | $134.50M | $128.30M | $147.30M | $128.00M | $115.10M | $131.10M | 16.1% | -6.2% |
| Nebulized Tyvaso | $126.00M | $127.20M | $125.70M | $141.80M | $154.40M | $163.80M | $142.70M | $159.20M | $139.90M | $145.00M | $136.90M | $120.70M | 16.1% | -18.4% |
| Orenitram | $125.70M | $135.60M | $121.20M | $131.10M | $123.90M | $120.70M | $107.80M | $113.20M | $107.10M | $106.20M | $84.10M | $92.00M | 16.0% | +1.5% |
| Unituxin | $65.20M | $53.60M | $62.30M | $47.90M | $58.40M | $58.20M | $67.50M | $61.10M | $51.70M | $58.40M | $54.20M | $51.30M | 8.3% | +11.6% |
| Other | $6.80M | $5.30M | $6.60M | $6.90M | $5.50M | $5.00M | $5.50M | $5.50M | $4.90M | $6.20M | $3.90M | $1.90M | 0.9% | +23.6% |
| Adcirca | $6.70M | $2.90M | $7.80M | $9.70M | $6.50M | $6.00M | $4.70M | $7.00M | $5.70M | $6.40M | $6.80M | $7.30M | 0.9% | +3.1% |
By region
| Revenue | Q2 26 | Q1 26 | Q4 25 | Q3 25 | Q2 25 | Q1 25 | Q4 24 | Q3 24 | Q2 24 | Q1 24 | Q4 23 | Q3 23 | % of revenue | YoY |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| United States | $733.60M | $744.20M | $752.80M | $774.80M | $759.80M | $749.60M | $705.70M | $717.30M | $675.20M | $641.50M | $585.90M | $584.60M | 93.7% | -3.4% |
| ROW | $49.70M | $37.30M | $37.40M | $24.70M | $38.80M | $44.80M | $30.20M | $31.60M | $39.70M | $36.20M | $28.80M | $24.80M | 6.3% | +28.1% |
From the segment and revenue-disaggregation notes of United Therapeutics's 10-K and 10-Q filings (XBRL). Fourth-quarter figures are the fiscal year less the first nine months. Segment names follow the company's own labels and can change when it reorganizes.